Similar articles

• Cost-effectiveness of apixaban versus other new oral anticoagulants for stroke prevention in atrial fibrillation.

  Lip GY, Kongnakorn T, Phatak H, Kuznik A, Lanitis T, Liu LZ, Iloeje U, Hernandez L, Dorian P. Lip GY, et al. Clin Ther. 2014 Feb 1;36(2):192-210.e20. doi: 10.1016/j.clinthera.2013.12.011. Epub 2014 Feb 6. Clin Ther. 2014. PMID: 24508420
• Oral anticoagulants for prevention of stroke in atrial fibrillation: systematic review, network meta-analysis, and cost effectiveness analysis.

  [No authors listed] [No authors listed] BMJ. 2018 May 23;361:k2295. doi: 10.1136/bmj.k2295. BMJ. 2018. PMID: 29793960 Free PMC article. No abstract available.
• Cost effectiveness of novel oral anticoagulants for stroke prevention in atrial fibrillation depending on the quality of warfarin anticoagulation control.

  Janzic A, Kos M. Janzic A, et al. Pharmacoeconomics. 2015 Apr;33(4):395-408. doi: 10.1007/s40273-014-0246-7. Pharmacoeconomics. 2015. PMID: 25512096
• Cost-Effectiveness of Novel Oral Anticoagulants for Stroke Prevention in Non-Valvular Atrial Fibrillation.

  Singh SM, Wijeysundera HC. Singh SM, et al. Curr Cardiol Rep. 2015 Aug;17(8):61. doi: 10.1007/s11886-015-0618-4. Curr Cardiol Rep. 2015. PMID: 26081245 Review.
• Meta-Analysis of Effectiveness and Safety of Oral Anticoagulants in Atrial Fibrillation With Focus on Apixaban.

  Bai Y, Shi XB, Ma CS, Lip GYH. Bai Y, et al. Am J Cardiol. 2017 Nov 1;120(9):1689-1695. doi: 10.1016/j.amjcard.2017.07.072. Epub 2017 Aug 1. Am J Cardiol. 2017. PMID: 28844510 Review.